3591 Background: Adjuvant chemotherapy is offered to most pts with Stage III CRC, and to a
subset with Stage II disease deemed at high-risk for recurrence. Nevertheless, risk …

Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early
relapse detection may have a major impact on treatment decisions and patient management …

9 Background: ctDNA-based post-surgical detection of molecular residual disease (MRD) is
known to be predictive of a high risk of recurrence. Here, we report the first results of …

4009 Background: The clinical utility of tracking circulating tumor DNA (ctDNA) as a non-
invasive biomarker for detecting minimal residual disease (MRD) and stratifying patients …

Background: Circulating tumor DNA (ctDNA) has emerged as a biomarker that can define
the risk of recurrence after curative-intent surgery for patients with colorectal cancer (CRC) …

Background: Early detection of disease recurrence has been shown to improve survival in
patients with colorectal cancer (CRC). Previous studies have analyzed circulating tumor …

5 Background: For patients (pts) with colon cancer (CC), the detection of circulating tumor
DNA (ctDNA) is associated with persistent disease after resection and outperforms …

Simple Summary Circulating tumor DNA (ctDNA) is a minimally invasive biomarker useful for
monitoring minimum residual disease, recurrence, and treatment response in colorectal …

3602 Background: ctDNA identifies patients (pts) at high risk for disease recurrence post
CRC resection (post-op). Current ctDNA residual disease detection approaches assess only …

Introduction Circulating tumor DNA (ctDNA) has been increasingly recognized as a
promising minimally-invasive biomarker that could identify patients with minimal residual …